ZEALAND PHARMA A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 650 DKK | -0.15% |
|
+5.26% | +74.17% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Calendar
2024-06-12
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
650
DKK
Average target price
785.6
DKK
Spread / Average Target
+20.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +74.17% | 5.92B | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.57B | |
| +3.23% | 22.82B | |
| -10.44% | 18.19B | |
| -41.74% | 16.54B | |
| -13.31% | 16.5B | |
| +2.44% | 13.39B | |
| +27.89% | 11.1B |
- Stock Market
- Equities
- ZEAL Stock
- News Zealand Pharma A/S
- Zealand Pharma Appoints New CFO
